Welcome to the e-CCO Library!

OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kucha, P.(1,2)*;Walkiewicz, D.(3);Wieszczy, P.(2,4);Reguła, J.(1,2);Zagórowicz, E.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
Year: 2022
Source: ECCO'22
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Allocca, M.(1);Dell’Avalle, C.(2);Furfaro, F.(2);Craviotto, V.(2);Zilli, A.(2);D'Amico, F.(2);Peyrin-Biroulet, L.(3);Fiorino, G.(1);Danese, S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Van Limbergen1, K. Dunn2, E. Wine3, R. Sigall Boneh4, J. Bielawski2, A. Levine4

Created: Thursday, 30 January 2020, 10:12 AM
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
Year: 2022
Source: ECCO'22
Authors: Lin, S.(1,2);Kennedy, N.A.(1,2);Saifuddin, A.(3,4);Muñoz Sandoval, D.(5);Reynolds, C.J.(5);Seoane, R.C.(6);Kottoor, S.H.(4);Pieper, F.P.(5);Lin, K.M.(5);Butler, D.K.(5);Chanchlani, N.(1,2);Nice, R.(2,7);Chee, D.(1,2);Bewshea, C.(2);Janjua, M.(1,2);McDonald, T.J.(7);Sebastian, S.(8,9);Alexander, J.L.(4,10);Constable, L.(4);Lee, J.C.(11,12,13);Murray, C.D.(11);Hart, A.L.(3);Irving, P.M.(14,15);Jones, G.R.(16,17);Kok, K.B.(18,19);Lamb, C.A.(20,21);Lees, C.W.(16,22);Altmann, D.M.(6);Boyton, R.J.(5,23);Goodhand, J.R.(1,2);Powell, N.(4,10);Ahmad, T.(1,2); CLARITY IBD
Created: Friday, 11 February 2022, 3:52 PM
OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study
Year: 2021
Source: ECCO'21 Virtual
Authors: Derikx, L.(1,2);Siakavellas, S.(2);Derr, L.(2);Williams, L.(2);Nikolas, P.(2);Jenkinson, P.(2);Lucaciu, L.(2);Constantine-Cooke, N.(3);Covil, K.(2);Murdoch, L.(2);Jones, G.R.(2,4);Lees, C.(2,5)
Created: Wednesday, 2 June 2021, 4:12 PM
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Barnhoorn*1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen - de Jong1, H. Verspaget1, L. Hawinkels1

Created: Friday, 22 February 2019, 9:41 AM
OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ehrström, A.(1)*;Jansson, S.(1);Malham, M.(1);Wewer, V.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Vermeire1, W. Sandborn2, F. Baert3, S. Danese4, T. Kobayashi5, E.V. Loftus Jr6, S. Bhatia7, K. Kisfalvi8, M. Rosario9, W. Zhang10, G. D’Haens11

Created: Thursday, 30 January 2020, 10:12 AM
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Brunet, E.(1,2)*;Selva, A.(3,4);Bas-Cutrina, F.(5);Brujats, A.(6,7);Caballol, B.(8);Gomez, B.(9);Gonzalez, C.(7);Busquets, D.(10);Monfort, D.(11);Vera, D.P.(12);Maristany, E.(13);Cirera, G.(14);Torres, G.(15);Castro-Poceiro, J.(16);Lopez, J.(17);Gonzalez-Gonzalez, L.(18);Marquez-Mosquera, L.(19);Gallach, M.(20);Esteve, M.(21);Tremosa, G.(22);Torra, S.(23);Robles, V.(24);Rodríguez-Lago, I.(25);Calvet, X.(2,26,27);
Created: Friday, 14 July 2023, 10:43 AM
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Shin*1, N. Ha1, D. Bae1, D-h. Suh1, J-y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S-M. Lee3, S-k. Seo3, J. W. Lee4, J. S. Kim4,5

Created: Friday, 22 February 2019, 9:41 AM
OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Pangan, A.(3);Greenbloom, S.(4);D'Haens, G.(5);Panes, J.(6);Juillerat, P.(7);Lindsay, J.O.(8);Loftus Jr, E.V.(9);Sandborn, W.J.(10);Reinisch, W.(11);Sanchez Gonzalez, Y.(3);Huang, B.(3);Xie, W.(3);Liu, J.(3);Weinreich, M.A.(3);Panaccione, R.(12)
Created: Wednesday, 2 June 2021, 4:12 PM
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
Year: 2022
Source: ECCO'22
Authors: Dignass, A.(1);Rubin, D.(2);Bressler, B.(3);Huang, K.H.(4);Shipitofsky, N.(4);Germinaro, M.(4);Zhang, H.(4);Johanns, J.(4);Feagan, B.(5);Sandborn, W.(6);Sands, B.(7);Hisamatsu, T.(8);Lichtenstein, G.(9);Panes, J.(10);Allegretti , J.(11); QUASAR Investigators
Created: Friday, 11 February 2022, 3:52 PM
OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Ben-Horin1, J. Leszczyszyn2, R. Dudkowiak2, A. Lahat3, B. Gawdis-Wojnarska4, A. Pukitis5, M. Horynski6, K. Farkas7, J. Kierkus8, M. Kowalski9, B.D. Ye10, W. Reinisch11, S.J. Lee12, S.H. Kim13, M.R. Kim13, Y.A. Kim13, H.N. Kim14, S. Schreiber15

Created: Thursday, 30 January 2020, 10:12 AM
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
Created: Friday, 11 February 2022, 3:52 PM
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Fumery*1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11

Created: Friday, 22 February 2019, 9:41 AM
OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire , S.(2);Zhou, W.(3);Pangan, A.(4);Siffledeen, J.(5);Hébuterne, X.(6);Nakase, H.(7);Higgins, P.(8);Chen, M.H.(9);Sanchez-Gonzalez, Y.(3);Huang, B.(3);Xie, W.(4);Liu, J.(4);Weinreich, M.(4);Pannaccione, R.(10)
Created: Wednesday, 2 June 2021, 4:12 PM
OP24: Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, Z.(1)*;Le, K.(1);Zhou, X.(1);Alexander, J.(1);Lin, S.(2);Bewshea, C.(2);Chanchlani, N.(2);Nice, R.(3);McDonald, T.(3);Lamb, C.(4);Sebastian, S.(5);Kok, K.(6);Lees, C.(7);Hart, A.(1);Pollok, R.(8);Boyton, R.(9);Altmann, D.(10);Pollock, K.(9);Goodhand, J.(2);Kennedy, N.(2);Ahmad, T.(2);Powell, N.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP25 Biologics before surgery for IBD: Are they associated with post-operative infectious outcomes? Results from the national surgical quality improvement programme inflammatory bowel disease collaborative
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Holubar1, X. Jai1, T. Hull1, N. Hyman2, S. Ramamoorthy3, S. Einsenstein3, National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative

Created: Thursday, 30 January 2020, 10:12 AM
OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet, L.(1);Dotan, I.(2,3);Hibi, T.(4);Taliadouros, V.(5);Oortwijn, A.(5);Zhao, S.(6);Zhang, J.(6);Hsieh, J.(6);Feagan, B.(7,8)
Created: Wednesday, 2 June 2021, 4:12 PM